Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Rhea-AI Summary
Minerva Neurosciences (Nasdaq: NERV) reported Q4 and FY2025 results and business updates on March 11, 2026. The company completed an $80.0M upfront private placement with potential additional proceeds up to $120.0M contingent on warrant exercises and trial outcomes.
Minerva plans to initiate a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia in Q2 2026 (~380 patients, 12-week primary endpoint) with topline data expected in 2H 2027. Cash was ~$82.4M at December 31, 2025; GAAP net loss for 2025 was $293.4M driven by non-cash preferred stock and warrant accounting.
Positive
- Received $80.0M upfront private placement proceeds in October 2025
- Initiation of confirmatory Phase 3 roluperidone trial planned for Q2 2026
- Phase 3 primary endpoint: ~380 patients over a 12-week period; topline expected 2H 2027
- Cash, cash equivalents and restricted cash of $82.4M at December 31, 2025
- Potential additional proceeds of up to $120.0M from warrant exercises and milestone-linked Tranche B
Negative
- GAAP net loss of $293.4M for the year ended December 31, 2025
- Recorded $321.5M non-cash loss on issuance of convertible preferred stock and warrants in 2025
- Series A preferred convertible into 37.8M common shares and warrants potentially convertible into 56.8M common shares (significant dilution risk)
- Total GAAP liabilities of $233.8M at December 31, 2025, including a warrant liability of $171.5M
News Market Reaction – NERV
In the Mar 11 session, NERV declined 8.06%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.5% during that session. Argus tracked a trough of -4.5% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 earnings | Positive | +4.1% | Reported Q3 results and detailed $80M upfront plus up to $200M financing. |
| Aug 14 | Q2 2025 earnings | Neutral | +25.4% | Outlined required 52-week confirmatory trial and lower quarterly R&D and G&A. |
| May 13 | Q1 2025 earnings | Positive | -0.1% | Reported narrowed net loss, reduced R&D expenses, and stable G&A with $17.4M cash. |
| Feb 25 | FY 2024 results | Positive | +0.0% | Showed lower R&D and G&A, swing to FY 2024 net income and $21.5M cash. |
| Nov 05 | Q3 2024 earnings | Positive | +1.7% | Reported net income for Q3 2024 with reduced operating expenses and $26.6M cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and business update releases for NERV have more often coincided with positive or flat price reactions, with only one modest divergence.
Across recent earnings and annual results, Minerva has repeatedly tied financial updates to progress on roluperidone and regulatory interactions. Prior quarters highlighted reduced R&D spending, tighter G&A control, and key financing steps such as the $80 million private placement disclosed with Q3 2025 results. Cash positions ranged from $15.3M to over $21.5M, while net results swung between losses and brief profitability. Today’s full-year 2025 update continues this pattern of combining financial detail with Phase 3 planning and capital structure implications.
Key Terms
phase 3 medical
new drug application regulatory
private placement financial
convertible preferred stock financial
warrant liability financial
non-gaap financial measures financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027
BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided business updates and reported financial results for the fourth quarter and year ended December 31, 2025.
Business Updates
Strategic Financing
On October 23, 2025, Minerva received
“Strengthened by the recent financing and our general alignment with the U.S. Food and Drug Administration (“FDA”) on trial design, we are working towards initiation of the confirmatory Phase 3 trial with roluperidone for the treatment of negative symptoms of schizophrenia in the second quarter,” said Dr. Remy Luthringer, Chairman and CEO of Minerva Neurosciences. “With the
Roluperidone - Potentially the First Treatment for Negative Symptoms of Schizophrenia
- Roluperidone is the only investigational therapy, to date, to demonstrate significant and clinically meaningful improvements on the primary negative symptoms of schizophrenia.
- Minerva has achieved general alignment with FDA on the confirmatory Phase 3 trial design.
- The Phase 3 trial remains on track to initiate in the second quarter of 2026, with a trial design similar to Minerva's two previous studies. The first phase of the trial has a primary efficacy endpoint to evaluate the improvement in negative symptoms with roluperidone 64 mg against placebo in approximately 380 patients over a 12-week period, with results expected in 2H 2027. This will be followed by a safety phase to evaluate relapse rates in patients treated with roluperidone 64 mg compared to patients treated with antipsychotics, as discussed with FDA.
- Minerva believes roluperidone could potentially shift the treatment paradigm for negative symptoms of schizophrenia.
Minerva hosted a live discussion with key opinion leaders (KOLs) on February 3, 2026, “Roluperidone: From Unmet Need to Reality,” featuring Greg Strauss, PhD, Franklin Professor of Psychology at the University of Georgia, and Brian Kirkpatrick, MD, MSPH, Peters Professor of Psychiatry at the University of Arkansas for Medical Sciences. Topics included patient burden, assessment challenges, and the upcoming confirmatory Phase 3 trial of roluperidone. The webcast is available at: https://ir.minervaneurosciences.com/static-files/23ad74a8-ed16-4c15-bc03-f00d18704126
Fourth Quarter 2025 and Year End Financial Results
Research and development (R&D) expense: For the three months ended December 31, 2025 and 2024, R&D expense was
General and administrative (G&A) expense: For the three months ended December 31, 2025 and 2024, G&A expense was
Non-cash interest expense: For the years ended December 31, 2025 and 2024, non-cash interest expense was zero and
Other income: For the years ended December 31, 2025 and 2024, Other income was zero and
Loss on issuance of convertible preferred stock and warrants: In conjunction with the October 2025 private placement, Minerva issued 80,000 shares of Series A Convertible Preferred Stock, which was convertible into 37.8 million shares of common stock. The fair value of the Series A Convertible Preferred Stock on the date of issuance was
Warrant issuance cost: In conjunction with the October 2025 private placement, Minerva incurred offering issuance costs of
Gain (Loss) on Change in Fair Value of Warrant Liability: For years ended December 31, 2025 and 2024, the change in fair value of the Warrant Liability was a gain of
Total Liabilities: Under U.S. Generally Accepted Accounting Principles (“GAAP”), for the years ended December 31, 2025 and 2024, total liabilities were
Net loss for the three months ended December 31, 2025: Under GAAP, net loss for the three months ended December 31, 2025 was
Net (loss) income for the year ended December 31, 2025: Under GAAP, net loss for the year ended December 31, 2025 was
Cash Position: Cash, cash equivalents and restricted cash at December 31, 2025 were approximately
* Definitions of the non-GAAP measures used by Minerva and a reconciliation of such measures to the related GAAP financial measure can be found under the sections below titled “Non-GAAP Financial Measures” and “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Non-GAAP Financial Measures
In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Minerva also presents adjusted non-GAAP financial measures.
Non-GAAP financial measures are included with the intent of providing investors with an understanding of Minerva’s historical financial results and trends and to facilitate comparisons between periods. In addition, these non-GAAP financial measures are among the indicators that Minerva’s management uses for planning and forecasting purposes and measuring Minerva’s performance. Minerva believes that these non-GAAP financial measures, when considered together with U.S. GAAP measures, can enhance the understanding of its financial and operating performance. Non-GAAP financial measures have no standardized meaning and investors are cautioned that, unlike financial measures prepared in accordance with U.S. GAAP, non-GAAP measures may not be comparable with the calculation of similar measures for other companies. The limitations of using non-GAAP financial measures as performance measures are that they provide a view of Minerva’s results of operations without including all events during a period and may not provide a comparable view of Minerva’s performance to other companies in the biopharmaceutical industry. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate the business.
Non-GAAP total liabilities is defined as GAAP total liabilities, excluding warrant liability and liability related to the sale of future royalties.
Non-GAAP adjusted net (loss) income is defined as GAAP net (loss) income, adjusted to exclude non-cash items related to: (i) stock-based compensation expense, (ii) interest expense for the sale of future royalties, (iii) other non-cash income, (iv) loss on issuance of convertible preferred stock and warrants and (v) changes in fair value of warrant liability.
Non-GAAP adjusted net (loss) income per share, basic and diluted, is defined as non-GAAP adjusted net (loss) income divided by weighted average shares outstanding, basic and diluted.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to implied or express statements regarding Minerva’s belief that it has reached alignment with the FDA on the path to initiate the confirmatory Phase 3 trial of roluperidone for the treatment of negative symptoms of schizophrenia; the expected timeline, design and conduct of that trial, including the timing of its results; the aggregate amount of proceeds to be received from the October 2025 financing upon warrant exercise; Minerva’s expected funding through the confirmatory Phase 3 trial for roluperidone, the resubmission of its NDA to the FDA and a commercial launch of roluperidone in the US, if approved; and Minerva’s belief that roluperidone could potentially shift the treatment paradigm for negative symptoms of schizophrenia. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, the inability to predict with certainty the level of expenditures and resources required for the confirmatory Phase 3 trial for roluperidone and other operational matters following Minerva’s plans to refocus efforts on the successful execution of the Phase 3 trial; Minerva’s future financial performance and position may not improve, resulting in difficulties in implementing Minerva’s business strategy, and plans and objectives for future operations; the expected sufficiency of Minerva’s existing cash resources and runway may not be accurate resulting in the need for additional financing sooner than anticipated or unexpected liquidity constraints; the internal and external costs required for Minerva’s ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause Minerva to use cash more quickly than expected or to change or curtail some of Minerva’s plans or both; trials and studies may be delayed and may not have satisfactory outcomes, and earlier trials and studies may not be predictive of later trials and studies; the design and rate of enrollment for clinical trials, including the current design of the Phase 3 confirmatory trial evaluating roluperidone may not enable successful completion of the trial(s); the commercial opportunity for roluperidone in negative symptoms of Schizophrenia may be smaller than anticipated; Minerva may be unable to obtain and maintain regulatory approvals, including uncertainties associated with the development and timing of Minerva’s interactions with the FDA; Minerva may experience uncertainties inherent in the initiation and completion of clinical trials and clinical development; the need to align with collaborators or partners may hamper or delay development and regulatory efforts or increase costs; uncertainties of patent protection and litigation; general economic conditions; and other factors that are described under the caption “Risk Factors” in Minerva’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 11, 2026. Copies of reports filed with the SEC are posted on Minerva’s website at http://ir.minervaneurosciences.com/. The forward-looking statements in this press release are based on information available to Minerva as of the date hereof, and Minerva disclaims any obligation to update any forward-looking statements, except as required by law.
Contacts:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
fahlholm@minervaneurosciences.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
| CONDENSED CONSOLIDATED BALANCE SHEET DATA | |||||||
| (Unaudited) | |||||||
| December 31, 2025 | December 31, 2024 | ||||||
| (in thousands) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 82,302 | $ | 21,362 | |||
| Restricted cash | 100 | 100 | |||||
| Prepaid expenses and other current assets | 698 | 807 | |||||
| Total current assets | 83,100 | 22,269 | |||||
| Equipment, net | - | 6 | |||||
| Goodwill | 14,869 | 14,869 | |||||
| Total assets | $ | 97,969 | $ | 37,144 | |||
| LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 639 | $ | 1,608 | |||
| Accrued expenses and other current liabilities | 1,651 | 1,229 | |||||
| Total current liabilities | 2,290 | 2,837 | |||||
| Long-term liabilities: | |||||||
| Warrant liability | 171,465 | - | |||||
| Liability related to the sale of future royalties | 60,000 | 60,000 | |||||
| Total liabilities | 233,755 | 62,837 | |||||
| Series A convertible preferred stock | 4,962 | - | |||||
| Stockholders' deficit: | |||||||
| Common stock | 4 | 1 | |||||
| Additional paid-in capital | 548,047 | 369,683 | |||||
| Accumulated deficit | (688,799 | ) | (395,377 | ) | |||
| Total stockholders' deficit | (140,748 | ) | (25,693 | ) | |||
| Total liabilities, redeemable preferred stock and stockholders' deficit | $ | 97,969 | $ | 37,144 | |||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended December 31, (in thousands, except per share amounts) | Twelve Months Ended December 31, (in thousands, except per share amounts) | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 2,174 | $ | 1,983 | $ | 5,759 | $ | 11,899 | ||||||||
| General and administrative | 2,808 | 2,539 | 9,344 | 9,949 | ||||||||||||
| Total operating expenses | 4,982 | 4,522 | 15,103 | 21,848 | ||||||||||||
| Loss from operations | (4,982 | ) | (4,522 | ) | (15,103 | ) | (21,848 | ) | ||||||||
| Foreign exchange losses (gains) | (21 | ) | 10 | (56 | ) | (2 | ) | |||||||||
| Investment income | 547 | 240 | 948 | 1,272 | ||||||||||||
| Non-cash interest expense for the sale of future royalties | - | - | - | (4,562 | ) | |||||||||||
| Other income | - | - | - | 26,579 | ||||||||||||
| Loss on issuance of convertible preferred stock and warrants | (321,499 | ) | - | (321,499 | ) | - | ||||||||||
| Warrant issuance cost | (3,103 | ) | - | (3,103 | ) | - | ||||||||||
| Changes in fair value of warrant liability | 45,390 | - | 45,390 | - | ||||||||||||
| Net (loss) income | $ | (283,668 | ) | $ | (4,272 | ) | $ | (293,423 | ) | $ | 1,439 | |||||
| Net (loss) income per share, basic | $ | (25.51 | ) | $ | (0.56 | ) | $ | (34.67 | ) | $ | 0.19 | |||||
| Weighted average shares outstanding, basic | 11,118 | 7,569 | 8,464 | 7,569 | ||||||||||||
| Net (loss) income per share, diluted | $ | (25.51 | ) | $ | (0.56 | ) | $ | (34.67 | ) | $ | 0.19 | |||||
| Weighted average shares outstanding, diluted | 11,118 | 7,569 | 8,464 | 7,574 | ||||||||||||
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
| RECONCILIATION OF TOTAL LIABILITIES - NON-GAAP | |||||||
| (Unaudited) | |||||||
| December 31, 2025 | December 31, 2024 | ||||||
| (in thousands) | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 639 | $ | 1,608 | |||
| Accrued expenses and other current liabilities | 1,651 | 1,229 | |||||
| Total current liabilities | 2,290 | 2,837 | |||||
| Long-term liabilities: | |||||||
| Warrant liability | 171,465 | - | |||||
| Liability related to the sale of future royalties | 60,000 | 60,000 | |||||
| Total liabilities - GAAP | 233,755 | 62,837 | |||||
| Reconciling items: | |||||||
| Warrant liability | (171,465 | ) | - | ||||
| Liability related to the sale of future royalties | (60,000 | ) | (60,000 | ) | |||
| Total liabilities - non-GAAP | $ | 2,290 | $ | 2,837 | |||
| RECONCILIATION OF ADJUSTED NET (LOSS) INCOME - NON-GAAP | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended December 31, (in thousands, except per share amounts) | Twelve Months Ended December 31, (in thousands, except per share amounts) | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net (loss) income – GAAP | $ | (283,668 | ) | $ | (4,272 | ) | $ | (293,423 | ) | $ | 1,439 | |||||
| Reconciling items: | ||||||||||||||||
| Stock-based compensation expense | 459 | 250 | 1,327 | 1,326 | ||||||||||||
| Non-cash interest expense for the sale of future royalties | - | - | - | 4,562 | ||||||||||||
| Other income | - | - | - | (26,579 | ) | |||||||||||
| Loss on issuance of convertible preferred stock and warrants | 321,499 | - | 321,499 | - | ||||||||||||
| Changes in fair value of warrant liability | (45,390 | ) | - | (45,390 | ) | - | ||||||||||
| Adjusted net (loss) income – non-GAAP | $ | (7,100 | ) | $ | (4,022 | ) | $ | (15,987 | ) | $ | (19,252 | ) | ||||
| Net (loss) income per share, basic – GAAP | $ | (25.51 | ) | $ | (0.56 | ) | $ | (34.67 | ) | $ | 0.19 | |||||
| Weighted average shares outstanding, basic | 11,118 | 7,569 | 8,464 | 7,569 | ||||||||||||
| Net (loss) income per share, diluted – GAAP | $ | (25.51 | ) | $ | (0.56 | ) | $ | (34.67 | ) | $ | 0.19 | |||||
| Weighted average shares outstanding, diluted | 11,118 | 7,569 | 8,464 | 7,574 | ||||||||||||
| Reconciling items: | ||||||||||||||||
| Stock-based compensation expense | 0.04 | 0.03 | 0.16 | 0.18 | ||||||||||||
| Non-cash interest expense for the sale of future royalties | - | - | - | 0.60 | ||||||||||||
| Other income | - | - | - | (3.51 | ) | |||||||||||
| Loss on issuance of convertible preferred stock and warrants | 28.91 | - | 37.98 | - | ||||||||||||
| Changes in fair value of warrant liability | (4.08 | ) | - | (5.36 | ) | - | ||||||||||
| Net (loss) income per share, basic – non-GAAP | $ | (0.64 | ) | $ | (0.53 | ) | $ | (1.89 | ) | $ | (2.54 | ) | ||||
| Weighted average shares outstanding, basic | 11,118 | 7,569 | 8,464 | 7,569 | ||||||||||||
| Net (loss) income per share, diluted – non-GAAP | $ | (0.64 | ) | $ | (0.53 | ) | $ | (1.89 | ) | $ | (2.54 | ) | ||||
| Weighted average shares outstanding, diluted | 11,118 | 7,569 | 8,464 | 7,574 | ||||||||||||
